
Kyle R Brimacombe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11872364/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Discovery and Optimization of 2 <i>H</i> -1λ ² -Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer. Journal of Medicinal Chemistry, 2021, 64, 4913-4946.	2.9	12
2	Optimization of ether and aniline based inhibitors of lactate dehydrogenase. Bioorganic and Medicinal Chemistry Letters, 2021, 41, 127974.	1.0	2
3	Pyrazole-Based Lactate Dehydrogenase Inhibitors with Optimized Cell Activity and Pharmacokinetic Properties. Journal of Medicinal Chemistry, 2020, 63, 10984-11011.	2.9	30
4	Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Central Science, 2020, 6, 672-683.	5.3	684
5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular Pharmacology, 2019, 96, 629-640.	1.0	22
6	Discovery and optimization of piperazine-1-thiourea-based human phosphoglycerate dehydrogenase inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 1727-1739.	1.4	23
7	Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space. ACS Central Science, 2018, 4, 1727-1741.	5.3	32
8	High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2. Journal of Biological Chemistry, 2018, 293, 13750-13765.	1.6	46
9	Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays. Scientific Reports, 2017, 7, 12758.	1.6	59
10	Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH). Journal of Medicinal Chemistry, 2017, 60, 9184-9204.	2.9	98
11	PKM2 activation sensitizes cancer cells to growth inhibition by 2-deoxy-D-glucose. Oncotarget, 2017, 8, 90959-90968.	0.8	14
12	A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate. Nature Chemical Biology, 2016, 12, 452-458.	3.9	389
13	Structure activity relationships of human galactokinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 721-727.	1.0	20
14	Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo. Nature, 2015, 522, 216-220.	13.7	336
15	Inhibition of Glutathione Peroxidase Mediates the Collateral Sensitivity of Multidrug-resistant Cells to Tiopronin. Journal of Biological Chemistry, 2014, 289, 21473-21489.	1.6	37
16	Identification of ML251, a Potent Inhibitor of <i>T. brucei and T. cruzi</i> Phosphofructokinase. ACS Medicinal Chemistry Letters, 2014, 5, 12-17.	1.3	27
17	Structure–activity relationship studies and biological characterization of human NAD+-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 630-635.	1.0	13
18	Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nature Chemical Biology, 2012, 8, 839-847.	3.9	614

Kyle R Brimacombe

#	Article	IF	CITATIONS
19	Collateral Sensitivity of Multidrug-Resistant Cells to the Orphan Drug Tiopronin. Journal of Medicinal Chemistry, 2011, 54, 4987-4997.	2.9	35
20	Synthesis and Structure–Activity Evaluation of Isatin-β-thiosemicarbazones with Improved Selective Activity toward Multidrug-Resistant Cells Expressing P-Glycoprotein. Journal of Medicinal Chemistry, 2011, 54, 5878-5889.	2.9	101
21	Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 2593-2598.	3.3	50
22	<i>N-desmethyl</i> -Loperamide Is Selective for P-Clycoprotein among Three ATP-Binding Cassette Transporters at the Blood-Brain Barrier. Drug Metabolism and Disposition, 2010, 38, 917-922.	1.7	40
23	A Dual-Fluorescence High-Throughput Cell Line System for Probing Multidrug Resistance. Assay and Drug Development Technologies, 2009, 7, 233-249.	0.6	53
24	Muscleblindâ€like 1 is a negative regulator of TGFâ€Î²â€dependent epithelial–mesenchymal transition of atrioventricular canal endocardial cells. Developmental Dynamics, 2009, 238, 3266-3272.	0.8	18
25	CELF-mediated alternative splicing is required for cardiac function during early, but not later, postnatal life. Journal of Molecular and Cellular Cardiology, 2009, 46, 395-404.	0.9	20
26	Cloning and embryonic expression patterns of the chicken CELF family. Developmental Dynamics, 2007, 236, 2216-2224.	0.8	26